Precision medicine, or personalized medicine, takes into account a patient’s genetics, lifestyle, and individual needs in order to provide the best disease management strategy. Nicolas Villain, MD, PhD, AP-HP Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France, discusses how precision medicine may become favorable in the treatment of Alzheimer’s disease (AD). This is because AD is a very complex disease that can affect individual patients differently. Recently, there have been discussions of three types of AD, based on genetic susceptibility, as well as research identifying the impact of co-pathologies that commonly occur with AD. Dr Villain therefore suggests that these should be used to provide precise diagnoses for patients and by extension, could help better design clinical trials and individualized treatment options. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.